By Mette Lauritzen PhD, Product Marketing Manager, Nuclear Molecular Imaging, Bruker BioSpin Different types of tumours, and their varying reactions to treatment, make the search for new effective cancer therapies incredibly challenging. Preclinical in vivo imaging methods are helping to obtain further knowledge of tumour morphology, progression, and biomarker expression by enabling the visualisation of […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!